

Cardinal Health Announces New Strategic Agreements at CIT 2017 to Expand Cordis' Cardiology Product Offerings in China

Beijing, China, March 31, 2017 — Cardinal Health today announced two new strategic agreements that will enable Cordis, Cardinal Health's interventional vascular business, to rapidly expand its cardiology product offering in China. These strategic agreements will add new percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, manufactured both in China and internationally, to the Cordis' portfolio. PTCA balloon catheters play a key role in the treatment of patients undergoing percutaneous coronary intervention (PCI). In China, more than 500,000 PCI procedures are performed each year.¹

“These strategic announcements demonstrate our commitment to rapidly expand Cordis' strong and diversified portfolio of products in interventional cardiology. With our expertise in the cardiovascular space, Cardinal Health and Cordis will continue to deliver the high quality solutions aligned with government priorities to support patient needs,” said Patrick Holt, President, Cardinal Health Medical Products, Asia Pacific.

Strategic Agreements with China and Internationally-Manufactured product offerings

- Cardinal Health signed a strategic agreement with Brosmed that enables Cordis to exclusively commercialize Brosmed's PTCA balloon catheters in China. The strategic agreement leverages Cordis' expertise and marketing network to promote two of Brosmed's PTCA balloons, including Brosmed's Artimes, a pre-dilation semi-compliance PTCA balloon, and Apollo, a post-dilation high pressure PTCA balloon in China. Brosmed's Artimes and Apollo are manufactured in Guangdong Province, China. The products are approved by the China Food and Drug Administration (CFDA) and the United States Food and Drug Administration (FDA), and are available in 30 countries.
- Cardinal Health has also signed a strategic agreement that enables Cordis to commercialize Kaneka's comprehensive portfolio of semi- and non-compliant workhorse PTCA balloon catheters in China. Starting in January 2017, Cordis has exclusively commercialized Ikazuchi Rev and Fortis II, under the Kaneka brand name. Upon future approval* in China, Cordis will also commercialize Ikazuchi Zero and Raiden 3. Kaneka's workhorse PTCA balloon catheters have a low-entry profile and new hydrophilic coating that facilitate access to calcified lesions or lesions that require higher crossability.

Cordis will continue to commercialize its EMPIRA line of pre-dilation and post-dilation PTCA balloons along with the Brosmed and Kaneka products in China.

“Cordis, as a Cardinal Health company, has significantly expanded our offerings in China during the last 12 months with several new products in interventional cardiovascular,” said Jessie Lian, General Manager of Cordis China. “We are committed to ensuring Chinese patients have access to high quality cardiovascular care, from access to intervention and closure.”

Cardiovascular disease has been the leading cause of mortality and morbidity in China in recent years. According to a China National Centre for Cardiovascular Diseases report, an estimated 41 percent of all deaths each year in China are attributed to cardiovascular disease, and it is estimated that one cardiovascular death occurs every 10 seconds.² The projected number of annual cardiovascular events is estimated to

increase by more than 50 percent from 2010 to 2030, based on ageing and population growth factors.³

About Cardinal Health

Cardinal Health is a global, integrated healthcare services and products company, providing customized solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with more than 37,000 employees in nearly 60 countries, Cardinal Health ranks among the top 25 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter and connect on LinkedIn at [linkedin.com/company/cardinal-health](https://www.linkedin.com/company/cardinal-health).

[1] April, 2016, 19th CCIF, release by Prof. Huo Yong (□□□)

[2] Report of Cardiovascular Diseases in China (2012). National Center for Cardiovascular Diseases, China.

[3] Moran A, Gu D, Zhao D, Coxson P, Wang YC et al (2010). Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-China. *Circ Cardiovasc Qual Outcomes* 3:243-252

*[*Ikazuchi Zero and Raiden 3 are not currently approved or commercially available today in China.]*

<http://cardinalhealth.mediaroom.com/CordisCIT>